The unconjugated faecal bile acid profiles of 14 patients with colorectal cancer, nine patients with polyps and 10 controls were compared using gas 
Epidemiological studies have implicated dietary fat of animal origin as an important aetiological factor in the development of colorectal cancer'2 which may be related to altered faecal bile acids.3 Bile acids given either orally,4 or rectally,56 have been shown to have a tumour promoting effect in rat models for colorectal cancer.
The mechanisms by which bile acids may produce these effects are uncertain. Bile acids may be mutagenic,78 but some of the techniques used have been questioned.-" Bile acids may directly damage DNA,'2 or chromatin.'3 Lithocholic acid has been shown to produce DNA strand breaks'4 and both chenodeoxycholic acid and lithocholic acid induce mitotic aneuploidy in yeast cells.'" Possible mechanisms which may explain an increase in colonic cell proliferation caused by bile acids, include effects on prostaglandin synthesis,'6 arachidonic acid release, '7 and protein kinase C activity. 18 Populations at greater risk of colorectal cancer have been found to excrete more faecal bile acids,3 19 The dried sample was resuspended in 5 ml acid water (pH [3] [4] which was then sonicated for five minutes. The suspension was then filtered through a lOx 1 cm column of Lipidex 1000. The column was converted to the aqueous form with 40 ml distilled water before use. The eluate was collected in a conical flask together with a column wash of 40 ml water (aqueous extract). Bile acids were recovered from the Lipidex 1000 by eluting the column with 40 ml 100% methanol into the original round bottomed flask.
The aqueous extract was then passed through a Sep Pak C18 cartridge (500 mg) prepared by previous washing with 5 ml 100% methanol followed by 10 ml water. Bile acids were eluted from the cartridge with 5 ml 100% methanol. The methanolic eluates were pooled in the original round bottomed flask and dried on a rotary evaporator.
The extracted bile acids were resuspended in 20 ml 72% ethanol. The pooled 'hexane' fraction (stored earlier) was resuspended in 10 ml 72% ethanol. The ethanolic suspensions were then filtered through a column of Amberlyst A-15 (2 cmx 10 cm), the column then being washed with a further 20 ml of 72% ethanol and the samples pooled. The column was prepared by suspending the Amberlyst A-15 in 72% ethanol for 24 hours before slurrying it into columns and allowing it to settle by gravity. This was then treated with 50 This was prepared in the acetate form by washing 100 g Lipidex-DEAP on a sintered glass funnel with 500 ml potassium acetate-KOH 0 5 M in 72% ethanol and then with further volumes of 72% ethanol until the eluate was neutral. It was then washed with 500 ml 0-1 M acetic acid in 72% ethanol and washed to neutrality again with 72% ethanol. The gel was slurried into glass columns and allowed to settle by gravity (z30 minutes) to give a column size of 0.5 x 14 cm. After the addition of the sample, it was eluted under pressure using nitrogen (0.5-1.0 Kg cm-2) to give a flow rate of 50-80 drops per minute. The column was washed with 9 ml 72% ethanol (pH 7) to give a fraction comprising neutral compounds and any esterfied bile acids. Unconjugated bile acids were obtained by elution with 7.5 ml 0-15 M acetate in 72% ethanol (apparent pH 3.8, adjusted with ammonium hydroxide) followed by 4-5 ml 72% ethanol. The remaining glycine conjugated, taurine conjugated and sulphated bile acid fractions were obtained by continued stepwise elutions with acetate buffers, but are not further considered in this report.
The unconjugated fractions were dried on a rotary evaporator and taken up in methanol as required.
DERIVITISATION
The internal standard (62.5 nmol coprostanol) was added to the sample. Diazomethane was freshly prepared using 0.54 g KOH dissolved in 14 ml 90% methanol and 2.86 g N-methyl-nnitroso-p-toluenesulphonamide in 40 15 minutes, using helium as the carrier gas. Detection was by flame ionisation using hydrogen and air at 290°C together with helium as a make up gas to improve the detection limit. The integration system was a PU3202 computer utilising PU6000 software (Phillips Scientific). Ultra pure gases were used and were further purified before entry into the chromatograph using the following filters; oxyfilter, moisture filter and charcoal filter x 2 (Chrompack, London, UK). 
Results

PATIENTS
There were no significant differences in the ages, weights, or stool frequency between the three groups. Transit times and daily stool weights are shown in Table I .
All the cancer patients had adenocarcinomas: two had Dukes's stage A, seven had B, and five had C. The polyps varied in size from 0 5 cm to 1-0 cm and five showed dysplastic changes (one mild and four moderate dysplasia). BILE 
ACIDS
The mean recovery of the radiolabelled standard was 92.9% (7 11) (SD). A typical chromatogram is shown in the Figure; 16 unconjugated bile acids were identified during this study (Table  II) . From our own observations (unpublished) and those of others,45 sulphated and conjugated bile acids represent less than 10% of the total bile (Table II) . There were no significant differences in the proportions of total chenodeoxycholic acid or cholic acid derivatives between the three groups (Table IV) . The proportion of metabolites of chenodeoxycholic acid and cholate was, however, higher in the cancer group, as reflected by lower ratios of chenodeoxycholic acid and cholate to their total derivatives (Table IV) . The overall proportion of the secondary bile acids was highest among the cancer patients when compared with both polyp patients and controls (Table V) . No significant differences were found in lithocholic acid:deoxycholic acid ratio or the lithocholic acid:deoxycholic acidxtotal faecal bile acid index when the groups were compared (Table V) .
The proportion of secondary bile acids in each group was found to correlate strongly with both transit time and stool weight (rs=0.717, p<001 and rs= -0* 527, p<0*01 respectively).
Discussion
One of the key elements of this study was the exercise of tight control over variables which may influence faecal bile acid profiles; age, transit time, gall stones, cholecystectomy, hepatic function, hepatic metastases, previous surgery, and antibiotics.
Not only is there a significant day to day variation in faecal bile acid excretion, but faecal bile acid concentrations may vary between different areas of the same stool.' A minimum complete three day stool collection with homogenisation has been shown to be necessary to minimise variation and most previous studies, The differences observed in cancer patients are more difficult to explain, as the faecal bile acid profiles of cancer patients in our study were different from those of polyps and controls. We would suggest that an altered metabolism (possibly related to gut transit time) may occur at the large polyp or cancer stage. This, with or without an increased absorption of faecal secondary bile acids may account for the differences observed in both faecal and biliary bile acids.
Neither the ratio of lithocholic acid: deoxycholic acid, or lithocholic acid:deoxycholic acid x total faecal bile acid were significantly increased in patients with colorectal cancer or polyps. This suggests that such indices are unlikely to provide useful markers for the identification of colorectal cancer risk as previously proposed.3738
In conclusion we have shown a significantly increased faecal bile acid concentration in patients with adenomatous polyps and an increased proportion of secondary bile acids in the faeces of patients with established colorectal cancer. This study lends further support to the theory that these compounds may have some role in the pathogenesis of polyps and colorectal cancer. 
